Meghan Leary

Meghan Leary

Auto-generated profile, based on publicly available information

Meghan Leary

Boston University School of Medicine, Boston, MA 02118, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2015 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
SHSarah Heerboth
Sarah Heerboth
GHGenevieve Housman
Genevieve Housman
MLMeghan Leary
Meghan Leary
MLMckenna Longacre
Mckenna Longacre
SBShannon Byler
Shannon Byler
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
EMT and MET comprise the processes by which cells transit between epithelial and mesenchymal states, and they play integral roles in both normal development and cancer metastasis. This article reviews these processes and the molecular pathways that contribute to them. First, we compare embryogenesis and development with cancer metastasis. We then discuss the signaling pathways and the differential expression and down‐regulation of receptors in both tumor cells and stromal cells, which play a role in EMT and metastasis. We further delve into the clinical implications of EMT and MET in several types of tumors, and lastly, we discuss the role of epigenetic events that regulate EMT/MET processes. We hypothesize that reversible epigenetic events regulate both EMT and MET, and thus, also regulate the development of different types of metastatic cancers.

4 December 2018 in Cancers
Verified
Journal Article
Open access
PDF file
MLMeghan Leary
Meghan Leary
SHSarah Heerboth
Sarah Heerboth
KLKarolina Lapinska
Karolina Lapinska
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
Cancer drug resistance is an enormous problem. It is responsible for most relapses in cancer patients following apparent remission after successful therapy. Understanding cancer relapse requires an understanding of the processes underlying cancer drug resistance. This article discusses the causes of cancer drug resistance, the current combination therapies, and the problems with the combination therapies. The rational design of combination therapy is warranted to improve the efficacy. These processes must be addressed by finding ways to sensitize the drug-resistant cancers cells to chemotherapy, and to prevent formation of drug resistant cancer cells. It is also necessary to prevent the formation of cancer progenitor cells by epigenetic mechanisms, as cancer progenitor cells are insensitive to standard therapies. In this article, we emphasize the role for the rational development of combination therapy, including epigenetic drugs, in achieving these goals.

1 March 2014
Verified
Journal Article
Closed access
SBShannon Byler
Shannon Byler
SGSarah Goldgar
Sarah Goldgar
SHSarah Heerboth
Sarah Heerboth
MLMeghan Leary
Meghan Leary
GHGenevieve Housman
Genevieve Housman
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar

Verified
Journal Article
Open access
PDF file
MLMckenna Longacre
Mckenna Longacre
NSNicole A. Snyder
Nicole A. Snyder
GHGenevieve Housman
Genevieve Housman
MLMeghan Leary
Meghan Leary
KLKarolina Lapinska
Karolina Lapinska
Sibaji SarkarSibaji Sarkar
Sibaji Sarkar
Breast cancer persists as the most common cause of cancer death in women worldwide. Ovarian cancer is also a significant source of morbidity and mortality, as the fifth leading cause of cancer death among women. This reflects the continued need for further understanding and innovation in cancer treatment. Though breast and ovarian cancer usually present as distinct clinical entities, the recent explosion of large-scale -omics research has uncovered many overlaps, particularly with respect to genetic and epigenetic alterations. We compared genetic, microenvironmental, stromal, and epigenetic changes common between breast and ovarian cancer cells, as well as the clinical relevance of these changes. Some of the most striking commonalities include genetic alterations of BRCA1 and 2, TP53, RB1, NF1, FAT3, MYC, PTEN, and PIK3CA; down regulation of miRNAs 9, 100, 125a, 125b, and 214; and epigenetic alterations such as H3K27me3, H3K9me2, H3K9me3, H4K20me3, and H3K4me. These parallels suggest shared features of pathogenesis. Furthermore, preliminary evidence suggests a shared epigenetic mechanism of oncogenesis. These similarities, warrant further investigation in order to ultimately inform development of more effective chemotherapeutics, as well as strategies to circumvent drug resistance.